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Tab. 1.  The effects of cadmium and selenium ions, BBP, and OTA on enzyme 
activity of rat CYP1A and 2C. 
_________________________________________________________________ 
 
Pollutant EROD activity Sudan I oxidation Diclofenac  Testosterone 
       4’-hydroxylation 16α-hydroxylation 
           (CYP1A)a       (CYP1A1)      (CYP2C6)         (CYP2C11) 
                                                                                        
 
CdCl2    83±0.09*    46±4.27***   89±0.44*   100±6.43                       
Na2SeO3   95±0.83   100±2.62   94±5.59    82±1.01** 
OTA   100±7.50    99±4.93      NEb    18±1.24*** 
BBP    83±1.24*    25±1.27***    7±0.26***    68±12.48** 
 
 
Data are expressed as % of control without pollutants. Values in the table are 
averages ± standard deviations of three experiments (n = 3). The incubation 
mixtures contained 0.5 mg.mL-1 microsomal protein, 10 µmol.L-1 AAI (dissolved in 
distilled water), the NADPH-generating system containing 1 mmol.L-1 NADP+, and 
100 µmol.L-1 pollutant [heavy metal ions dissolved in distilled water, OTA dissolved 
in 0.1 mol.L-1 NaHCO3 (pH 7) or BBP dissolved in acetonitrile] (see Materials and 
Methods). Values significantly different from control incubations without pollutants; 
*P<0.1, **P<0.01, ***P<0.001 (Student’s t-test).  
aIsoforms of CYP whose enzyme activity is measured are shown in brackets.  
bNE, no effect. 
  
Fig. 1. Scheme of detoxication and bio-activation of AAI in organisms. dA-AAI, 7-
(deoxyadenosin-N6-yl)aristolactam I; dG-AAI, 7-(deoxyguanosin-N2-yl)aristolactam 












Fig. 2. HPLC of AAI (peak r.t. at 37.7 min) and AAIa metabolite (peak r.t. at 24.5 
min) produced by hepatic microsomes of control (untreated) rats incubated with AAI 
and the NADPH-generating system. The peaks with the characterised metabolite 

















Fig. 3. AAI oxidation to AAIa catalysed by rat hepatic microsomes in the presence of 
heavy metal ions present in incubation mixtures, CdCl2 (A), Pb(CH3COO)2 [Pb(Ac)2; 
B), Na2SeO3 (C), Na2HASO4·7H2O (D). Values are given as means ± standard 
deviations of three experiments (n = 3). Values significantly different from incubation 
with buffer only: *P<0.1, **P<0.01 (Student’s t-test). The incubation mixtures 
contained 0.5 mg.mL-1 microsomal protein, 1–100 µmol.L-1 heavy metal ions 
dissolved in distilled water, the NADPH-generating system containing 1 mmol.L-1  
NADP+, and 10 µmol.L-1 AAI dissolved in distilled water (see Materials and 
Methods). Numbers above the columns (“F”) indicate fold changes in amounts of 






































































































Na2HAsO4 7H20 concentration [µmol.L
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Fig. 4. AAI oxidation to AAIa catalysed by rat hepatic microsomes in the presence 
of phthalates. In incubation mixtures, dibutylphthalate (DBP, A), 
butylbenzylphthalate (BBP, B) and bis(2-ethyhexyl)phthalate (DEHP, C) all 
dissolved in acetonitrile were used. Values are given as means ± standard 
deviations of three experiments (n = 3). Values significantly different from 
incubation with acetonitrile only: *P<0.1, **P<0.01 (Student’s t-test). The 
incubation mixtures contained 0.5 mg.mL-1 microsomal protein, 1–100 µmol.L-1 
phthalates, the NADPH-generating system containing 1 mmol.L-1  NADP+, and 10 
µmol.L-1 AAI dissolved in distilled water (see Materials and Methods). Numbers 
above the columns (“F”) indicate fold changes in amounts of AAIa compared to 










































































Fig. 5. AAI oxidation to AAIa catalysed by rat hepatic microsomes in the presence of 
OTA dissolved in 0.1 mol.L-1 NaHCO3 (pH 7). Values are given as means ± standard 
deviations of three experiments (n = 3). Values significantly different from incubation 
with 0.1 mol.L-1 NaHCO3 (pH 7) only: ***P<0.001 (Student’s t-test). The incubation 
mixtures contained 0.5 mg.mL-1 microsomal protein, 1–100 µmol.L-1 OTA, the 
NADPH-generating system containing 1 mmol.L-1  NADP+, and 10 µmol.L-1  AAI 





































Fig. 6. Combined effect of cadmium and selenium ions, BBP and OTA on AAI 
detoxication to AAIa. Incubations with CdCl2, Na2SeO3 and OTA (A) and in 
combination of these compounds with BBP (B) were carried out. Values are given as 
means ± standard deviations of three experiments (n = 3). Values significantly 
different from incubation with buffer/acetonitrile only: *P<0.1, **P<0.01, ***P<0.001 
(Student’s t-test). The incubation mixtures contained 0.5 mg.mL-1 microsomal 
protein, 100 µmol.L-1 CdCl2, Na2SeO3, dissolved in distilled water, OTA dissolved in 
0.1 mol.L-1 NaHCO3 (pH 7) or BBP dissolved in acetonitrile, the NADPH-generating 
system containing 1 mmol.L-1  NADP+, and 10 µmol.L-1  AAI dissolved in distilled 
water (see Materials and Methods). Numbers above the columns (“F”) indicate fold 
changes in amounts of AAIa compared to incubations without the above mentioned 
compounds. 
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